176 related articles for article (PubMed ID: 2433872)
21. Psoriatic arthritis treated with oral colchicine.
Seideman P; Fjellner B; Johannesson A
J Rheumatol; 1987 Aug; 14(4):777-9. PubMed ID: 3668983
[TBL] [Abstract][Full Text] [Related]
22. Caffeine consumption and methotrexate dosing requirement in psoriasis and psoriatic arthritis.
Swanson DL; Barnes SA; Mengden Koon SJ; el-Azhary RA
Int J Dermatol; 2007 Feb; 46(2):157-9. PubMed ID: 17269967
[TBL] [Abstract][Full Text] [Related]
23. The changes in expression of ICAM-3, Ki-67, PCNA, and CD31 in psoriatic lesions before and after methotrexate treatment.
Yazici AC; Tursen U; Apa DD; Ikizoglu G; Api H; Baz K; Tasdelen B
Arch Dermatol Res; 2005 Dec; 297(6):249-55. PubMed ID: 16215763
[TBL] [Abstract][Full Text] [Related]
24. Increased insulin-like growth factor binding protein-3 expression level in psoriatic tissue before and after systemic treatment with cyclosporine A and methotrexate.
Ozden MG; Ilter N; Suer OE; Solaktekin N; Gürer MA
Int J Dermatol; 2008 Nov; 47(11):1177-83. PubMed ID: 18986456
[TBL] [Abstract][Full Text] [Related]
25. Etretinate (Tigason) and betamethasone valerate (Celeston valerate) in the treatment of psoriasis. A double-blind, randomized, multicenter trial.
Christiansen JV; Holm P; Møller R; Reymann F; Schmidt H
Dermatologica; 1982 Sep; 165(3):204-7. PubMed ID: 6751889
[No Abstract] [Full Text] [Related]
26. Effects of methotrexate and hydroxyurea on psoriatic epidermis. Preferential cytotoxic effects on psoriatic epidermis.
Smith C; Gelfant S
Arch Dermatol; 1974 Jul; 110(1):70-2. PubMed ID: 4418706
[No Abstract] [Full Text] [Related]
27. Psoriasis treatment with betamethasone dipropionate using short-term application and short-term occlusion.
Jaeger L
Acta Derm Venereol; 1986; 66(1):84-7. PubMed ID: 2424228
[TBL] [Abstract][Full Text] [Related]
28. [Our experience of psoriatic arthritis and psoriasis treatment with methotrexate (author's transl)].
Zbojanová M; Vlcek F; Trnavský K
Cesk Dermatol; 1980 Feb; 55(1):39-44. PubMed ID: 6988086
[No Abstract] [Full Text] [Related]
29. Pharmacokinetics of small doses of methotrexate in patients with psoriasis.
Kamel RS; al-Hakiem MH; Rademaker M; Meyrick Thomas RH; Munro DD
Acta Derm Venereol; 1988; 68(3):267-70. PubMed ID: 2455425
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the efficacy of topical caffeine in the treatment of psoriasis vulgaris.
Vali A; Asilian A; Khalesi E; Khoddami L; Shahtalebi M; Mohammady M
J Dermatolog Treat; 2005; 16(4):234-7. PubMed ID: 16249145
[TBL] [Abstract][Full Text] [Related]
31. Methotrexate markedly reduces the expression of vascular E-selectin, cutaneous lymphocyte-associated antigen and the numbers of mononuclear leucocytes in psoriatic skin.
Sigmundsdottir H; Johnston A; Gudjonsson JE; Bjarnason B; Valdimarsson H
Exp Dermatol; 2004 Jul; 13(7):426-34. PubMed ID: 15217363
[TBL] [Abstract][Full Text] [Related]
32. Disappointing results and low tolerability of photodynamic therapy with topical 5-aminolaevulinic acid in psoriasis. A randomized, double-blind phase I/II study.
Schleyer V; Radakovic-Fijan S; Karrer S; Zwingers T; Tanew A; Landthaler M; Szeimies RM
J Eur Acad Dermatol Venereol; 2006 Aug; 20(7):823-8. PubMed ID: 16898905
[TBL] [Abstract][Full Text] [Related]
33. [Double-blind-study on treatment with clobetasol-17-propionate and other topical corticoids (author's transl)].
Beck M; Berger C; Filipp N; Hundertmark U; Loewel R
Z Hautkr; 1981 Aug; 56(16):1066-70. PubMed ID: 7027655
[TBL] [Abstract][Full Text] [Related]
34. [Ambulatory external treatment of psoriasis vulgaris: comparison of the effectiveness of a dithranol and a glucocorticoid-containing preparation].
Przybilla B; Kaudewitz P
Z Hautkr; 1988 Jan; 63(1):60-2. PubMed ID: 3281386
[TBL] [Abstract][Full Text] [Related]
35. Cutaneous ulceration caused by methotrexate.
Kazlow DW; Federgrun D; Kurtin S; Lebwohl MG
J Am Acad Dermatol; 2003 Aug; 49(2 Suppl Case Reports):S197-8. PubMed ID: 12894123
[TBL] [Abstract][Full Text] [Related]
36. Correlation of the vasoconstriction assay and clinical activity in psoriasis.
Cornell RC; Stoughton RB
Arch Dermatol; 1985 Jan; 121(1):63-7. PubMed ID: 3881088
[TBL] [Abstract][Full Text] [Related]
37. Clinical and immunohistochemical evaluation of psoriatic plaques treated with topical 5-aminolaevulinic acid photodynamic therapy.
Fransson J; Ros AM
Photodermatol Photoimmunol Photomed; 2005 Dec; 21(6):326-32. PubMed ID: 16313245
[TBL] [Abstract][Full Text] [Related]
38. Clinical trial of a potent non-halogenated topical steroid, Budesonide.
Agrup G; Björnberg A; Elmros T; Groth O; Hannuksela M; Lassus A; Salde L; Skogh M; Thomsen K
Acta Derm Venereol; 1981; 61(2):180-2. PubMed ID: 6165205
[TBL] [Abstract][Full Text] [Related]
39. Association of disease severity with IL-1 levels in methotrexate-treated psoriasis patients.
Tamilselvi E; Haripriya D; Hemamalini M; Pushpa G; Swapna S
Scand J Immunol; 2013 Dec; 78(6):545-53. PubMed ID: 24283773
[TBL] [Abstract][Full Text] [Related]
40. [Cyclosporin A--dermatologic indications].
Mahrle G; Schulze HJ
Z Hautkr; 1990 Jan; 65(1):28-32, 37-9. PubMed ID: 2183505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
